梅奥诊所脑库对多系统萎缩MDS诊断标准的验证研究
该研究在梅奥诊所脑库1998至2021年间连续纳入352例临床或病理诊断多系统萎缩的患者,回顾性比较2022年国际帕金森病与运动障碍学会(MDS)新标准与2008年第二版共识标准的诊断准确性。结果显示MDS临床确立的多系统萎缩特异度达99%但敏感度仅16%,MDS临床 probable 多系统萎缩敏感度64%、特异度74%;第二版共识 probable 多系统萎缩敏感度72%、特异度52%,possible 多系统萎缩敏感度93%、特异度21%。MDS临床 probable 多系统萎缩的AUC最高为0.69。
要点
- MDS临床确立的多系统萎缩特异度99%、敏感度16%。
- MDS临床 probable 多系统萎缩敏感度64%、特异度74%。
- 第二版共识 probable 多系统萎缩敏感度72%、特异度52%。
核心结论
- MDS标准中临床确立的多系统萎缩具有高特异度,临床 probable 多系统萎缩具有中等敏感度和特异度。
- 仅凭临床特征即可获得高特异度,提示在MRI不易获得的地区也可实现高特异度的多系统萎缩诊断。
研究设计与样本
- 回顾性尸检队列研究,纳入梅奥诊所脑库1998年至2021年间连续临床或病理诊断多系统萎缩的患者352例(病理确诊多系统萎缩250例,非多系统萎缩102例)。
- 应用MDS标准与第二版共识标准,比较敏感度、特异度及受试者工作特征曲线下面积(AUC),并在临床亚型间及临床疑难病例间进行比较。
- 采用机器学习算法eXtreme Gradient Boosting识别贡献诊断性能的临床特征。
主要发现
- MDS标准临床确立多系统萎缩的敏感度16%、特异度99%;临床 probable 多系统萎缩的敏感度64%、特异度74%。
- 第二版共识标准 probable 多系统萎缩的敏感度72%、特异度52%;possible 多系统萎缩的敏感度93%、特异度21%。
- MDS临床 probable 多系统萎缩的AUC最高(0.69);诊断性能在临床亚型间无差异。
- 在临床疑难病例中,MDS临床确立多系统萎缩保持高特异度,MDS临床 probable 多系统萎缩的AUC最高(0.62)。
- MRI发现有助于高特异度;核心临床特征联合13项支持特征中任意2项及以上且无排除标准也可获得高特异度;支持特征中快速进展对预测多系统萎缩病理最重要。
关键数值与推荐
- MDS临床确立多系统萎缩:敏感度16%、特异度99%。
- MDS临床 probable 多系统萎缩:敏感度64%、特异度74%,AUC 0.69。
- 第二版共识 probable 多系统萎缩:敏感度72%、特异度52%。
- 第二版共识 possible 多系统萎缩:敏感度93%、特异度21%。
- 临床疑难病例中MDS临床 probable 多系统萎缩AUC 0.62。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The second consensus criteria in 2008 have been used in diagnosing multiple system atrophy (MSA). The International Parkinson and Movement Disorder Society (MDS) proposed new diagnostic criteria for MSA in 2022. This study aimed to compare the diagnostic accuracy between these 2 criteria and validate the clinical utility of the newly proposed criteria for MSA. METHODS: We conducted a retrospective autopsy cohort study of consecutive patients with a clinical or pathologic diagnosis of MSA from the Mayo Clinic brain bank between 1998 and 2021. We studied 352 patients (250 pathologically diagnosed MSA and 102 non-MSA); MDS criteria and the second consensus criteria were applied. The sensitivity, specificity, and area under the curve (AUC) of receiver operating characteristic curves were compared between these criteria. Comparison was conducted between clinical subtypes and among clinically challenging cases (those with different clinical diagnoses or those with suspected but undiagnosed MSA before death). We also used machine learning algorithm, eXtreme Gradient Boosting, to identify clinical features contributing diagnostic performance. RESULTS: The sensitivity and specificity of clinically established and probable MSA by the MDS criteria were 16% and 99% and 64% and 74%, respectively. The sensitivity and specificity of probable MSA and possible MSA by the second consensus criteria were 72% and 52% and 93% and 21%, respectively. The AUC of MDS clinically probable MSA was the highest (0.69). The diagnostic performance did not differ between clinical subtypes. In clinically challenging cases, MDS clinically established MSA maintained high specificity and MDS clinically probable MSA demonstrated the highest AUC (0.62). MRI findings contributed to high specificity. In addition, combining core clinical features with 2 or more from any of the 13 supporting features and the absence of exclusion criteria also yielded high specificity. Among supporting features, rapid progression was most important for predicting MSA pathology. DISCUSSION: The MDS criteria showed high specificity with clinically established MSA and moderate sensitivity and specificity with clinically probable MSA. The observation that high specificity could be achieved with clinical features alone suggests that MSA diagnosis with high specificity is possible even in areas where MRI is not readily available.
引用
- Sekiya H, Koga S, Murakami A, et al. Validation Study of the MDS Criteria for the Diagnosis of Multiple System Atrophy in the Mayo Clinic Brain Bank. Neurology. 2023. PMID: 37816641. doi:10.1212/WNL.0000000000207905
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。